( enhanced protection from chemotherapy-i...)MGI Pharma Summarizes Data Presented at the 2007 American Society,of Clinical Oncology (ASCO) Annual Meeting,Health

"The data presentations at ASCO demonstrate our commitment to advancing the discovery of clinical attributes that distinguish each of the oncology products in our portfolio," said Mary Lynne Hedley, Ph.D., Executive Vice President and Chief Scientific Officer of MGI PHARMA. "We look forward to advancing the scientific understanding of our product candidates and the presentation of data at future medical meetings."

Aloxi(R) Injection

Study Results on Receptor Interactions of Aloxi Versus Other 5-HT3 Receptor Antagonists

The results of studies characterizing the molecular ligand-receptor interactions of Aloxi and the other 5-HT3 receptor antagonists, ondansetron and granisetron, were reported. Competitive versus allosteric interactions between these agents and the 5-HT(3) receptor were examined in binding experiments using each unlabeled antagonist in competition with ((3)H)-antagonist. Concentrations of ((3)H)-antagonists were representative of the probable concentrations of each antagonist at the receptor site in vivo. Based on a plot of the concentration of unlabeled antagonist needed to observe half maximal binding (IC50) as a function of ((3)H)-antagonist concentration, Aloxi demonstrated dual action suggesting competitive and allosteric interactions with the 5-HT3 receptor. In contrast, ondansetron and granisetron exhibited strictly competitive antagonism.

The Aloxi allosteric interaction with the 5-HT3 receptor indicates that it has additional inhibitory potential at the primary receptor binding site compared to the other 5-HT3 receptor antagonists studied.

Study of a Single Day Combination of Aloxi, Dexamethasone and Aprepitant in Patients Receiving Moderately Emetogenic Chemotherapy

(MEC) Regimens

The results of a study evaluating the efficacy of Aloxi in combination with dexamethasone and apr
'"/>